Mario Polywka - Evotec AG Insider

Evotec AG -- USA Stock  

USD 26.47  0.00  0.00%

COO and Member of Management Board

Dr. Mario Polywka was Chief Operating Officer and Member of the Management Board at Evotec AG since November 28, 2007. In 1991, he was a founding chemist of Oxford Asymmetry International plc, became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr. Polywka was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr. Polywka ran a number of spinout companies from Oxford and Southampton Universities. Dr. Polywka received his Bachelors degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with postdoctoral studies on the biosynthesis of Penicillins with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994
Age: 53  COO Since 2007  Ph.D    
49 4056 0810  http://www.evotec.com
Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis. In May 2017, Dr. Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc.

Management Efficiency

The company has return on total asset (ROA) of 5.91 % which means that it generated profit of $5.91 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.68 % meaning that it generated $13.68 on every $100 dollars invested by stockholders.
The company has accumulated 9.53 M in total debt with debt to equity ratio (D/E) of 2.5 implying the company greatly relies on financing operations through barroing. Evotec AG has Current Ratio of 4.88 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 1 records

COO Since

John ArthurWestpac Banking Corporation
2011

Entity Summary

Evotec AG offer drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Hamburg, and employs 1,000 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators